JP2008538557A5 - - Google Patents

Download PDF

Info

Publication number
JP2008538557A5
JP2008538557A5 JP2008507557A JP2008507557A JP2008538557A5 JP 2008538557 A5 JP2008538557 A5 JP 2008538557A5 JP 2008507557 A JP2008507557 A JP 2008507557A JP 2008507557 A JP2008507557 A JP 2008507557A JP 2008538557 A5 JP2008538557 A5 JP 2008538557A5
Authority
JP
Japan
Prior art keywords
group
phenyl
lower alkyl
alkyl group
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008507557A
Other languages
English (en)
Japanese (ja)
Other versions
JP5035238B2 (ja
JP2008538557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2006/001523 external-priority patent/WO2006112685A1/en
Publication of JP2008538557A publication Critical patent/JP2008538557A/ja
Publication of JP2008538557A5 publication Critical patent/JP2008538557A5/ja
Application granted granted Critical
Publication of JP5035238B2 publication Critical patent/JP5035238B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008507557A 2005-04-22 2006-04-21 神経治療アゾール化合物 Expired - Lifetime JP5035238B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67453005P 2005-04-22 2005-04-22
US60/674,530 2005-04-22
PCT/KR2006/001523 WO2006112685A1 (en) 2005-04-22 2006-04-21 Neurotherapeutic azole compounds

Publications (3)

Publication Number Publication Date
JP2008538557A JP2008538557A (ja) 2008-10-30
JP2008538557A5 true JP2008538557A5 (enExample) 2012-03-08
JP5035238B2 JP5035238B2 (ja) 2012-09-26

Family

ID=37115369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008507557A Expired - Lifetime JP5035238B2 (ja) 2005-04-22 2006-04-21 神経治療アゾール化合物

Country Status (23)

Country Link
US (1) US7598279B2 (enExample)
EP (1) EP1879873B1 (enExample)
JP (1) JP5035238B2 (enExample)
KR (1) KR101286499B1 (enExample)
CN (1) CN101228138B (enExample)
AR (1) AR053065A1 (enExample)
AU (1) AU2006237798B2 (enExample)
BE (1) BE2021C524I2 (enExample)
BR (1) BRPI0607529B8 (enExample)
CA (1) CA2606258C (enExample)
DK (1) DK1879873T3 (enExample)
ES (1) ES2441765T3 (enExample)
FI (1) FIC20210018I1 (enExample)
FR (1) FR21C1027I2 (enExample)
MX (1) MX2007013197A (enExample)
MY (1) MY148589A (enExample)
NL (1) NL301106I2 (enExample)
PL (1) PL1879873T3 (enExample)
PT (1) PT1879873E (enExample)
RU (1) RU2418792C2 (enExample)
TW (1) TWI398249B (enExample)
WO (1) WO2006112685A1 (enExample)
ZA (1) ZA200709994B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
CA2686926C (en) 2007-05-14 2016-01-05 Sk Holdings Co., Ltd. Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
AU2008258599B2 (en) 2007-06-05 2013-06-13 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
CN102026988B (zh) * 2008-06-05 2013-07-03 爱思开生物制药株式会社 3-取代的丙胺化合物
AU2009348523B2 (en) * 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) * 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
ES2447295T3 (es) 2009-11-06 2014-03-11 Sk Biopharmaceuticals Co., Ltd. Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
JP6232384B2 (ja) * 2012-01-06 2017-11-15 ノバルティス アーゲー 複素環式化合物およびその使用方法
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
TWI655179B (zh) * 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
ITUA20161941A1 (it) * 2016-03-23 2017-09-23 Univ Degli Studi Di Siena Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
KR102421006B1 (ko) 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도
KR102421013B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
WO2018111002A1 (ko) 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 카바메이트 화합물을 포함하는 구강 붕해 정제
WO2018111003A1 (ko) 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
MY200159A (en) * 2016-12-14 2023-12-09 Sk Biopharmaceuticals Co Ltd Parenteral liquid preparation comprising carbamate compound
KR102901908B1 (ko) * 2016-12-14 2025-12-17 에스케이바이오팜 주식회사 운동신경세포 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
KR102635941B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
KR102900173B1 (ko) * 2016-12-14 2025-12-12 에스케이바이오팜 주식회사 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도
CN110290788A (zh) * 2016-12-14 2019-09-27 爱思开生物制药株式会社 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
ES3035674T3 (en) 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
EP3711757B1 (en) 2017-11-14 2025-05-07 SK Biopharmaceuticals Co., Ltd. Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
ES2973111T3 (es) 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
CN111432812A (zh) * 2017-11-14 2020-07-17 爱思开生物制药株式会社 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途
KR102900174B1 (ko) * 2017-11-14 2025-12-16 에스케이바이오팜 주식회사 근긴장증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
US20200268711A1 (en) 2017-11-14 2020-08-27 Sk Biopharmaceuticals Co., Ltd. Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome
BR112020009310A2 (pt) 2017-11-14 2020-10-13 Sk Biopharmaceuticals Co., Ltd. combinação e composição farmacêutica para a prevenção, alívio ou tratamento da esquizofrenia.
TWI826531B (zh) * 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
CN113242735A (zh) * 2018-09-21 2021-08-10 爱思开生物制药株式会社 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
IL281559B2 (en) * 2018-09-21 2025-06-01 Sk Biopharmaceuticals Co Ltd (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
KR20210062029A (ko) 2018-10-19 2021-05-28 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
US10611737B1 (en) 2019-10-24 2020-04-07 Sk Biopharmaceuticals Co., Ltd. Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity
AU2020389425B2 (en) * 2019-11-22 2026-03-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
JP2023536341A (ja) * 2020-08-06 2023-08-24 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む経口用固形製剤及びその製造方法
CN114317620B (zh) * 2020-09-29 2024-02-02 上海医药工业研究院 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法
AR125970A1 (es) 2021-05-28 2023-08-30 Sk Biopharmaceuticals Co Ltd Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato
CN115974799B (zh) * 2021-10-14 2024-08-13 成都百裕制药股份有限公司 氨基甲酸酯取代的醇衍生物及其在医药上的应用
ES2931000B2 (es) * 2022-07-14 2023-07-07 Univ Madrid Complutense Proceso para la preparación de cenobamato
CN115716810B (zh) * 2022-11-15 2026-02-13 江苏艾立康医药科技有限公司 一种西诺氨酯的晶体形式及其制备方法
CN118239901A (zh) * 2023-03-15 2024-06-25 江苏恩华药业股份有限公司 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体
GB202416518D0 (en) 2024-11-08 2024-12-25 Jazz Pharmaceuticals Research Uk Ltd Combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
DK181988A (da) * 1988-03-30 1989-10-01 Dumex Ltd As Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug
HU221190B1 (en) * 1991-08-22 2002-08-28 Warner Lambert Co Acyl-coenzyme-a-cholesterol-acyl-transferase (acat) inhibitor tetrazole-carboxamide derivatives
RU2298552C2 (ru) * 2001-06-25 2007-05-10 СК Корпорейшн Карбаматы 2-гетероциклил-1,2-этандиолов
US6770659B2 (en) * 2002-08-26 2004-08-03 Sk Corporation Benzoyl piperidine compounds
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds

Similar Documents

Publication Publication Date Title
MX2011008305A (es) Compuestos de piridazinona.
WO2009005110A3 (en) Halogen-containing organosulfur compound and use thereof
NZ601786A (en) Novel compounds and compositions and methods of use
IL189650A0 (en) Amino-5-[4-(difluoromethoxy) phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
EP2662352A3 (en) Method for Producing Phenylacetamide Compound
MA38540A1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
RU2009141611A (ru) Способ получения амидного соединения
MX2009006907A (es) Activador de glucocinasa.
JP2008505194A5 (enExample)
WO2008006043A3 (en) 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents
EP2292607A3 (en) Process for the synthesis of organic compounds
EA200970943A1 (ru) Новое пиримидиновое соединение, имеющее структуру дибензиламина, и лекарственное средство, включающее данное соединение
WO2005053403A3 (en) The use of n-arylhydrazine derivatives for combating non-crop pests
MY140489A (en) 1,2-di (cyclic) substituted benzene compounds
MX339557B (es) Composicion plaguicida y su uso.
EP2388000A3 (en) Neuroprotectant containing heterocyclic compound having specific structure
JP2009184932A5 (enExample)
MY160882A (en) Biocidal composition and method
WO2008129966A1 (ja) 有害生物防除組成物
PH12019500589A1 (en) Novel mesoionic insecticidal compound
RU2008136892A (ru) Способ получения соединения 5-алкокси-4-гидроксиметилпиразола
ES2536918T3 (es) Compuestos de benzoilpirazol y herbicidas que los contienen
TW200616972A (en) Process for preparing pyridazinone compounds
UA93888C2 (uk) Протитуберкульозна композиція, яка містить сполуки оксазолу
CA2660818A1 (en) Antibacterial agent and therapeutic agent for johne's disease containing the same